<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40953957</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1499-2752</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of rheumatology</Title><ISOAbbreviation>J Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jrheum.2025-0294</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3899/jrheum.2025-0294</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the validity of the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) in children with enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (jPsA) in a prospective clinical trial setting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">JUNIPERA (NCT03031782) is a phase 3, placebo-controlled withdrawal study investigating the safety and efficacy of secukinumab in children with ERA and jPsA. After 12 weeks of open-label treatment with secukinumab, patients were randomized 1:1 to secukinumab or placebo until disease flare or Week 52. JSpADA validity was assessed using 3 criteria: convergent validity (Spearman's correlation) at Week 12 with the Juvenile Arthritis Disease Activity Score in 10 joints (JADAS-10), clinical JADAS-10 (cJADAS-10), and physician global assessment of disease activity (PGA); discriminatory validity at Week 12 among patients with active or inactive disease and JIA ACR response criteria; and responsiveness to change in clinical disease activity from Weeks 12 to 52.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At Week 12, mean (SD) JSpADA scores showed moderate-to-good correlation with JADAS-10, cJADAS-10, and PGA scores (all Spearman &#x3c1; &gt; 0.4) and were higher among patients with active vs inactive disease (1.8 [1.3] vs 0.5 [0.8], P &lt; 0.001). Patients with improved disease activity from Weeks 12 to 52 had greater improvements in JSpADA than patients with worsening disease (-0.8 [1.1] vs 0.4 [1.0], P &lt; 0.001); patients with stable disease had minimal change in JSpADA (-0.1 [0.5]). Validity results were similar for ERA and jPsA.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results validate JSpADA as a disease activity measure for children with ERA and jPsA in a prospective clinical trial setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Pamela F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>P.F. Weiss, MD, MSCE, Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruperto</LastName><ForeName>Nicolino</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>N. Ruperto, MD, MPH, IRCCS Istituto Giannina Gaslini, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quebe-Fehling</LastName><ForeName>Erhard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>E. Quebe-Fehling, PhD, Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shew</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>A. Shew, DMSc, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pricop</LastName><ForeName>Luminita</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>L. Pricop, MD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieterse</LastName><ForeName>Christelle C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>C.C. Pieterse, BSc, Syneos Health, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Hermine I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>H.I. Brunner, MD, University of Cincinnati, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Paediatric Rheumatology INternational Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG) Investigative Sites</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Rheumatol</MedlineTA><NlmUniqueID>7501984</NlmUniqueID><ISSNLinking>0315-162X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>21</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40953957</ArticleId><ArticleId IdType="doi">10.3899/jrheum.2025-0294</ArticleId><ArticleId IdType="pii">jrheum.2025-0294</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>